Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

338 results
Display

Recent advances in cellular immunotherapy for lymphoid malignancies

Chung H, Cho H

Cellular immunotherapy with chimeric antigen receptor (CAR) T-cells has revolutionized the treatment of lymphoid malignancies. This review addresses the need for CAR expression in our endogenous T-cells to kill tumor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bloodless Treatment of Jehovah’s Witness Patients with Lymphoma and Multiple Myeloma

Kim JY, Jeong SY, Yoon SY, Lee MY, Lee N, Won JH, Kim KH

Background/Aims: Jehovah’s Witnesses refuse blood transfusions for religious reasons. Soonchunhyang University Hospital Seoul has operated a bloodless treatment center since 2000, and a database of bloodless treatment patients has been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Three Cases of Central Retinal Vein Occlusion Associated with Systemic Disease: Case Report

Koh EJ, Bang JW, Lee DH, Lee JH, Chang JW, Chung IK, Song Mk, Choi HJ

Purpose: To report three cases of central retinal vein occlusion (CRVO) in patients with unusual systemic diseases. Case summary: The first case involves a 51-year-old male who presented with reduced vision...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Extramedullary Plasmacytoma in Both Maxillary Sinuses

Seo M, Park JH, Kim SD, Choi KU, Cho KS

Plasmacytoma is a rare hematolymphoid malignancy. The three types of plasmacytoma, according to clinical features and morphological characteristics, include solitary bone plasmacytoma, extramedullary plasmacytoma (EMP), and multiple myeloma (MM). Although...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Photon-Counting Detector Computed Tomography: A Promising New Technique for Multiple Myeloma Evaluation That Warrants Further Investigation

Lee YH, Lee IS

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of Photon-Counting Detector Computed Tomography on Image Quality and Radiation Dose in Patients With Multiple Myeloma

Rau A, Neubauer J, Taleb L, Stein T, Schuermann T, Rau S, Faby S, Wenger S, Engelhardt M, Bamberg F, Weiss J

Objective: Computed tomography (CT) is an established method for the diagnosis, staging, and treatment of multiple myeloma. Here, we investigated the potential of photon-counting detector computed tomography (PCD-CT) in terms...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Kidney Transplantation and Clinical Outcomes in Patients With Multiple Myeloma: Evidence From the United States Nationwide Inpatient Sample

Yang B, Zhang L, Lu X

Purpose: Patients with multiple myeloma (MM) are prone to developing persistent renal insufficiency. Novel therapeutic medications have improved long-term survival, making kidney transplantation (KT) a viable treatment option for MM...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Identification of druggable genes for multiple myeloma based on genomic information

Satria RD, Irham LM, Adikusuma W, Puspitaningrum AN, Afief AR, Khair RE, Septama AW

Multiple myeloma (MM) is a hematological malignancy. It is widely believed that genetic factors play a significant role in the development of MM, as investigated in numerous studies. However, the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study

Byun JM, Park SS, Yoon SS, Ahn A, Kim M, Lee JY, Jeon YW, Shin SH, Yahng SA, Koh Y, Min CK

Background The goal of induction therapy for multiple myeloma (MM) is to achieve adequate disease control. Current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone; VRd) or quadruplet regimens (daratumumab, bortezomib-thalidomide-dexamethasone; D-VTd). In the absence of a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recent advances in the treatment of multiple myeloma

Jung SH

Background: Multiple myeloma (MM) is a malignant plasma cell neoplasm characterized by anemia, renal failure, hypercalcemia, and osteolytic bone lesions. Although it is a complex and challenging disease, recent advances...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study

Jung J, Kim K, Jung SH, Yoon SS, Lee JH, Kim JS, Shin HJ, Bang SM, Sohn SK, Suh C, Yoon DH, Kong SY, Min CK, Eom HS, The Korean Multiple Myeloma Working Party

Purpose A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma. Materials and Methods In this phase II...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma

Cho HJ, Jo JC, Lee YJ, Lee MW, Kim DY, Shin HJ, Im SN, Lee JH, Bae SH, Do YR, Lee WS, Kim MK, Jung J, Lee JM, Kim JH, Baek DW, Sohn SK, Moon JH

Background/Aims: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imaging for Multiple Myeloma according to the Recent International Myeloma Working Group Guidelines: Analysis of Image Acquisition Techniques and Response Evaluation in Whole-Body MRI according to MY-RADS

Son AY, Chung HW

Multiple myeloma (MM) is a malignant hematologic disease caused by the proliferation of clonal plasma cells in the bone marrow, and its incidence is increasing in Korea. With the development...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Application and Limitations of Myeloma Response Assessment and Diagnosis System (MY-RADS)

Kim DK, Park SS, Jung JY

Multiple myeloma, which is a proliferative disease of plasma cells that originate from a single clone, is the second most common hematologic malignancy following non-Hodgkin lymphoma. In the past, its...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Therapeutic Leukapheresis for Plasma Cell Leukemia Presenting with Hyperleukocytosis: The First Case in Korea

Park S, Park JH, Chung Y, Ko DH, Kim H

Plasma cell leukemia (PCL) is a rare plasma cell disorder. Although therapeutic plasma exchange has reportedly been performed for hypergammaglobulinemia in PCL, there are no reports of therapeutic leukapheresis (TL)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma

Tuncel FC, Serin I, Pehlivan S, Oyaci Y, Pehlivan M

Background The suppressor of cytokine signaling-1 (SOCS-1) functions to induce an appropriate immune response and is an essential physiological regulator of interferon signaling. DNA methylation involves adding a methyl group to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Spheno-Orbital Plasmacytoma as an Initial Presentation of Multiple Myeloma

Ahn S, Cha SH, Cho WH

Intracranial plasmacytoma is a rare neoplasm and a subtype of malignant plasma cell tumor. Most patients with plasma cell tumors are diagnosed with multiple myeloma, but 5%–10% of patients are...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study

Lee JM, Cho HJ, Moon JH, Sohn SK, Park B, Baek DW

Background: This study investigated the prognostic impact of spine magnetic resonance imaging (MRI) in patients newly diagnosed with multiple myeloma (MM). Methods: We retrospectively evaluated 214 patients who were newly diagnosed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world Data-based Adverse Drug Reactions Analysis of Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Ko M, Choi J, Kim S, Kim SH, Cho EJ, Cho YS, Koh YI, Oh JM

Objective: Pomalidomide is a latest-approved immunomodulatory drug used with dexamethasone for patients with relapsed or refractory multiple myeloma (RRMM). However, the real-world safety evidence remains unclear. Thus, we evaluated the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chimeric Antigen Receptor-T Cell Therapy

Byun JM, Yoon SS

Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr